www.angiosoma.com OTCBB: SOAN
HOUSTON, TX, May 14, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (OTC: SOAN) is excited to announce that the U.S. Patent Office has agreed to grant our patent application for our flagship pharmaceutical, Liprostin™ that is intended to treat Peripheral Artery Disease, or PAD.
We are told the market opportunity is significant with 8 million U.S. diagnosed cases of PAD costing $212 - $389 billion annually. PAD costs exceed diabetes, coronary artery disease and cancers. It is reported that 60% to 70% of diabetics contract peripheral artery disease, often resulting in amputation as treatment.